Genetic and Epigenetic Determinants in Autoinflammatory Diseases by Damiana Álvarez-Errico et al.
March 2017 | Volume 8 | Article 3181
Mini Review
published: 22 March 2017
doi: 10.3389/fimmu.2017.00318
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Alessandra Soriano, 
Università Campus Bio-Medico, Italy
Reviewed by: 
Christian Michael Hedrich, 
Harvard Medical School, USA  
Anne Cooke, 
University of Cambridge, UK
*Correspondence:
Esteban Ballestar  
eballestar@idibell.cat
Specialty section: 
This article was submitted to 
Inflammation, 
a section of the journal 
Frontiers in Immunology
Received: 23 December 2016
Accepted: 07 March 2017
Published: 22 March 2017
Citation: 
Álvarez-Errico D, Vento-Tormo R and 
Ballestar E (2017) Genetic and 
Epigenetic Determinants in 
Autoinflammatory Diseases. 
Front. Immunol. 8:318. 
doi: 10.3389/fimmu.2017.00318
Genetic and epigenetic Determinants 
in Autoinflammatory Diseases
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(IDIBELL), Barcelona, Spain
The concept of autoinflammation has evolved over the past 20 years, beginning with 
the discovery that mutations in the Mediterranean Fever (MEFV ) gene were causative 
of Familial Mediterranean Fever. Currently, autoinflammatory diseases comprise a wide 
range of disorders with the common features of recurrent fever attacks, prevalence of 
hyperreactive innate immune cells, and signs of inflammation that can be systemic or 
organ specific in the absence of pathogenic infection of autoimmunity. Innate immune 
cells from the myeloid compartment are the main effectors of uncontrolled inflammation 
that is caused in great extent by the overproduction of inflammatory cytokines such 
as IL-1β and IL-18. Defects in several signaling pathways that control innate immune 
defense, particularly the hyperreactivity of one or more inflammasomes, are at the core 
of pathologic autoinflammatory phenotypes. Although many of the autoinflammatory 
syndromes are known to be monogenic, some of them are genetically complex and 
are impacted by environmental factors. Recently, epigenetic dysregulation has surfaced 
as an additional contributor to pathogenesis. In the present review, we discuss data 
that are currently available to describe the contribution of epigenetic mechanisms in 
autoinflammatory diseases.
Keywords: autoinflammatory diseases, epigenetics, DnA methylation, non-genetic factors, cryopyrin-associated 
periodic syndromes, Familial Mediterranean Fever
inTRODUCTiOn
Autoinflammatory diseases are a growing group of debilitating and chronic conditions characterized 
by overt inflammation that is often systemic and manifests as recurrent fever episodes. Hyperreactive 
innate immune cells contribute largely to the pathogenesis of these diseases, and patients who 
display this pathology correlates with increased levels of acute-phase proteins and inflammatory 
cytokines in the plasma. Originally, the term autoinflammation was coined to describe the occur-
rence of apparently unprovoked episodes of inflammation in the absence of self-reactive T  cells 
and/or high titers of autoantibodies, as well as in the absence of any detectable infectious agent 
(1). Many of the autoinflammatory syndromes display systemic and/or organ-specific inflammatory 
features such as recurrent and episodic periodic fever, serositis, arthritis and/or cutaneous inflam-
mation, overproduction of IL-1β, and activation of innate immune cells, particularly monocytes (2). 
Albeit initially the term autoinflammatory diseases only applied to those prototypical hereditary 
monogenic periodic fever syndromes, such as cryopyrin-associated periodic syndromes (CAPS) and 
Familial Mediterranean Fever (FMF), the list has now expanded as a consequence of the application 
of emerging technologies, such as next-generation sequencing, and comprises an increasing number 
of newly described monogenic disorders caused by mutations of inflammation-related genes. There 
TAble 1 | Autoinflammatory disorders and evidence of epigenetic 
contribution to pathogeny.
Mutated gene Disease effector 
cytokine
Data on 
epigenetic 
regulation
Hereditary monogenic periodic fever syndromes
MEFV Familial Mediterranean Fever IL-1β Yes (38)
TNFRSF1A TRAPS IL-1β No
MVK Hyper IgD syndrome IL-1β No
NLRP3 Cryopyrin-associated 
periodic syndromes [familial 
cold autoinflammatory 
syndrome (FCAS), 
Muckle–Wells syndrome, 
neonatal-onset multisystem 
inflammatory disease/CINCA]
IL-1β Yes (40)
NLRC4 NLRC4-MAS IL-1β/IL-18 No
PSTPIP1 PAPA IL-1β No
NLRP12 FCAS2 IL-1β No
Antagonist deficiencies
IL1RN DIRA IL-1β No
IL36RN DITRA IL-36 No
Complex autoinflammatory disorder
Behçet IL-6/IL-1β Yes (41, 48, 
49)
CRO/chronic recurrent 
multifocal osteomyelitis
IL-10/IL-1β Yes (42, 43)
Crohn IL-19/IL-3/IL-27 Yes (50, 51)
2
Álvarez-Errico et al. Epigenetics in Autoinflammatory Diseases
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 318
is also increasing evidence that epigenetic dysregulation partici-
pates in the pathogenesis of these diseases [Table 1; reviewed by 
Stoffels and Kastner (3)]. In addition, autoinflammatory diseases 
also include a few multifactorial and complex diseases, such as 
Behçet’s disease and Crohn’s disease (CD), which not only involve 
the participation of multiple alleles but also a number of envi-
ronmental factors (2, 4). Also, it is now accepted that there is a 
continuum of disorders in the inflammatory spectrum that ranges 
from autoimmune diseases at one end to autoinflammatory at the 
other, with several mixed complex conditions that display both 
features of innate and adaptive immune dysregulation (5, 6). 
This growing spectrum of conditions indicates the existence of 
a highly complex etiology and pathophysiology of inflammatory 
diseases, even in the case of monogenic diseases, where addi-
tional agents, besides the causative gain-of-function mutations, 
may have a relevant impact on the clinical course of the disease. 
In autoinflammatory diseases, a failure in the regulation of the 
defense mechanisms of innate immune cells, which responds to 
pathogen-expressed molecules or molecules signaling cellular 
stress, and the orchestration of a response to such insults with 
the production of proinflammatory cytokines such as IL-1β or 
IL-18 (2) are central to pathology. Genetic inheritance in auto-
inflammatory disorders varies depending on the specific disease 
and has been a subject of controversy. FMF is mostly transmitted 
in an autosomal recessive manner, which requires mutations in 
both alleles of the Mediterranean Fever (MEFV) locus, encod-
ing the sensor protein pyrin that is expressed in neutrophils, 
eosinophils, and cytokine-activated monocytes (7). Interestingly, 
there have been reports of several cases of FMF patients that are 
heterozygous for the MEFV allele, with only one allele displaying 
a mutation or, in even rarer cases, no detectable mutation, and 
yet still associate with the development of disease (8–10). Several 
groups studying the FMF phenotype in MEFV mutation-negative 
patients found the phenotype to be milder, with a late disease 
onset and a lower rate of familiar history of FMF. However, the 
unequivocal existence of such mutation-free patients suggests the 
existence of additional causes for disease development including 
mutation in alternative genes, and perhaps the occurrence of 
epigenetic dysregulation. Identification of those alterations is 
essential for patient diagnosis and management.
In the case of CAPS, inherited dominant autosomal gain-of-
function mutations of NOD-like receptor, NLRP3 gene encoding 
cryopyrin, are responsible for the overactivation of the inflamma-
some (11–13). In fact, CAPS is a spectrum disorder that includes, 
in increasing order of severity, the familial cold autoinflammatory 
syndrome (FCAS), Muckle–Wells syndrome, and neonatal-onset 
multisystem inflammatory disease (NOMID), caused by sporadic 
de novo mutations in the same gene (otherwise termed chronic 
infantile neurologic cutaneous and articular syndrome/CINCA) 
(14). Several lines of evidence, including the existence of muta-
tions with different degrees of penetrance leading to a gradient of 
disease severity and heterogeneous phenotypes in terms of disease 
progression that arises from identical germline mutations, suggest 
that additional factors contribute to pathophysiology of hyperin-
flammation. Moreover, a great number of cases (as much as 40% 
in the case of NOMID/CINCA for conventional sequencing) are 
considered “genetic orphans,” i.e., patients without any identi-
fied associated mutations, which further supports this notion. 
In some of these cases, the existence of mosaicism restricted to 
the myeloid compartment has been reported; however, there 
is the possibility that, in some cases, non-genetic mechanisms 
could lead to autoinflammation. For example, it is plausible 
that, in addition to the occurrence of specific mutations, certain 
amplification loops establish vicious circles that increase IL-1β 
production and inflammation. The complexity of genome regula-
tion in autoinflammatory diseases is reflected in CAPS, where it is 
extensively agreed that the lack of genetic confirmation for some 
patients does not exclude their diagnosis (15). In the cases of 
complex autoinflammatory disorders where heritability models 
are not well established, it is entirely possible that, although there 
may be a genetic component that contributes to certain parts of 
disease, both genetic and environmental/epigenetic factors may 
define pathogenicity, and this applies to disorders like Behçet’s 
disease, inflammatory bowel disease (IBD), and chronic recurrent 
multifocal osteomyelitis (CRMO) among others. It has been long 
recognized that environmental factors contribute to the establish-
ment of pathological immune responses as well as the develop-
ment and severity of inflammatory immune disorders, and twin 
studies have been valuable to determine the extent of genetic and 
non-genetic contributions, such as in the case of IBD (16). Since 
epigenetic mechanisms establish a diversity of links between the 
environment and the regulation of the genome, understanding 
epigenetic control within the innate immune compartment is 
crucial to fully grasp the etiology of autoinflammatory disorders.
FiGURe 1 | Control of innate immune cell function. Monocyte cell membrane receptors as TLR4 and IL-1R allow communication between the cell and the 
environment. Engagement of the receptors by their ligands (LPS or IL-1β) triggers cell signaling cascades, allowing transcription factors, particularly NF-κB 
translocation into the nucleus, where it recognizes specific regions of the DNA and recruits other transcription factors, as well as epigenetic enzymes, like TET2 
(protein involved in DNA demethylation in myeloid cells). Both the binding of transcription factors to the DNA and the epigenetic modifications of the DNA will 
increase the expression of inflammatory genes, like the inflammasome complex components. Posttranscriptional modifications of inflammasome proteins play a 
crucial role in the formation of the inflammasome complex, leading to the activation of caspase-1, which then is able to process the proinflammatory cytokines IL1-β 
and IL-18 into mature bioactive IL-1β and IL-18 cytokines that are secreted to the external media, creating an inflammatory microenvironment. Importantly, IL-1β is 
able to amplify its own signal through the binding to IL-1R.
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COnTROl OF innATe iMMUne Cell 
FUnCTiOn
The acquisition of full host protection requires proper orches-
tration and balance between resistance and tolerance, with the 
former being necessary to maximally reduce pathogen burden 
and the latter to minimize self-tissue damage by inflammation 
(17). Innate immune cells, including monocytes, macrophages, 
and neutrophils, are in the first line of defense and hence are 
equipped with very specialized molecular machinery aimed at 
sensing and destroying invading pathogens and restoring homeo-
stasis. Pattern-recognition receptors that recognize pathogen-
associated molecular patterns, and non-microbial stress signals, 
known as danger-associated molecular patterns, constitute the 
sensors that trigger upon recognition of their substrates during 
an inflammatory response. Many of these receptors, including the 
toll-like receptors and C-type lectin receptors, are located on the 
cell membrane in contact with the extracellular milieu, whereas 
others are cytoplasmic, such as the inflammasome-participating 
NOD (nucleotide-binding oligomerization domain)-like 
receptors and AIM2 (absent in melanoma) family of receptors 
(18). Inflammasomes are a key component of such defensive 
machinery that consist of multimeric cytoplasmic platforms that 
ensemble upon recognition of an insult and respond by activating 
pro-caspase-1, leading to proteolytic processing and release of 
IL-1β and IL-18, and pyroptosis (Figure 1) (19, 20).
Innate immune cells, in particular monocytes and mac-
rophages, rely on epigenetically controlled functional reprogram-
ming in order to coordinate a proper response once stimuli are 
detected. During the differentiation of monocytes to macrophages, 
whole transcriptome and epigenome studies have shown that 
substantial changes affect ~19 Mbp, which is equivalent to 0.6% 
of the human genome. Epigenetic changes affect the activity of 
promoters (H3K4me3/H3K27ac) and distal regulatory elements 
that are presumed enhancers (H3K4me1/H3K27ac) to a similar 
extent (21).
ATP NLRP3 i
Bacterial toxins MVK mutaon
NLRC4 mutaon
Cryopyrin associated periodic 
syndromes (CAPS) 
Macrophage acvaon 
syndrome (MAS) 
Familial Mediterranean Fever ( FMF) 
& hyper IgD syndrome (HIDS) 
NLRP3
,
Uric acid, 
etc
mutat on 
(CAPS) RhoA inhibion
Pyrin mutaon
(FMF)PKNs inacvaon
(HIDS)
NLRC4
Flagellin  
(MAS)
PYRIN
ASC ASC
Pro-caspase 1 Pro-caspase 1Pro-caspase 1
Pro-IL-1β IL-1β
Pro-IL- LI81 -18
FiGURe 2 | Genetics of autoinflammatory diseases. Different inflammasome complexes are activated by different stimulus recognized by specific sensor 
molecules. Mutations of genes coding inflammasome proteins have been identified in autoinflammatory disorders. Gain-of-function mutations in NLRP3 gene have 
been detected in cryopyrin-associated periodic syndromes (CAPS), and mutations in NLRC4 gene have been observed in macrophage activation syndrome (MAS). 
The mechanistic explanation of the exacerbated inflammatory response for patients with Familial Mediterranean Fever (FMF) has recently been described. Mutation 
of pyrin in FMF patients causes a decrease in pyrin phosphorylation and deregulation of the inflammasome assembly. Higher amounts of inflammasome complex in 
the different diseases are associated with increased production of mature IL-1β and IL-18 inflammatory cytokines.
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The acquisition of a trained or tolerant state in macrophages 
upon encounter with an external stimulus of microbial origin is 
associated with changes in around 0.12% of the entire monocyte/
macrophage epigenome. There is also around 12% difference in 
the expression of transcription factors, which dictates the specific 
antimicrobial response, which also results in an immunological 
memory coded in the chromatin that will have an impact on how 
the cell reacts to future challenges. Furthermore, transcriptomic 
analysis of the acquisition of functional memory by macrophages 
reveals that it relies on ~200 transcription factors, ~100 kinases, 
and ~20 epigenetic enzymes that are differentially expressed in 
differentiated macrophages compared to their monocytic precur-
sors [reviewed in Ref. (22)].
DYSReGUlATiOn in innATe iMMUne 
CellS
Inflammatory responses aiming at destroying invading pathogens 
consist of very potent effector mechanisms that, if not properly 
regulated, could potentially be harmful to the host, as illustrated 
by the appearance of autoinflammatory disorders. In order to 
provide specificity to the innate immune response, different 
inflammasomes are defined by the sensor protein that triggers the 
assembly, such as the NLRP1 that recognizes muramyl dipeptide 
and anthrax lethal toxin (mouse NLRP1b) (23), NLRP3 that is 
triggered by several stress-induced molecules including mono-
sodic urate crystals or ATP, NLRC4 that recognizes cytosolic 
flagellin inflammasomes (24), and the AIM2 inflammasome that 
assembles in response to cytoplasmic DNA (Figure 2) (25–28). 
All these cytoplasmic innate immune receptors signal through the 
adaptor ASC (apoptosis-associated speck-like protein containing 
a caspase recruitment domain) that recruits caspase-1, leading 
to the activation of IL-1β and the processing of IL-18 (20). The 
group of autoinflammatory disorders caused by dysregulation 
of the inflammasomes is referred to as “inflammasomopathies” 
(29). Gain-of-function mutations of NLRP3 leading to aberrant 
activation of such inflammasomes are the cause of the CAPS 
spectrum disorders (30). For example, ATP, which is a very well 
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known NLRP3 inflammasome activator and a signal of cellular 
stress, is released in great amounts by CAPS monocytes when 
exposed to minute concentrations of inflammatory stimuli that 
do not induce a reaction in healthy counterparts. CAPS mono-
cytes appear to be more sensitive and prone to generate a stronger 
reaction to same amounts of LPS compared to monocytes from 
healthy donors, hence producing an inflammatory feedback loop 
by secreting large amounts of ATP that will further activate the 
inflammasome and aberrantly augment the production IL-1β and 
IL-18 (31). Mutations in NLRC4 have been shown to cause life-
threatening autoinflammatory macrophage activation syndrome 
with systemic overproduction of IL1-β and IL-18 as well as 
uncontrolled macrophage activation (32, 33).
In the case of FMF, it was not until this year that a mecha-
nistic explanation of exacerbated IL-1β release by mutated 
pyrin (coded by MEFV) was reported by Park and colleagues. 
Although pyrin does not seem to bind directly to bacterial 
products, it is phosphorylated by PKN1 and PKN2 in a RhoA 
GTPase-dependent manner, leading to inactivation of the 
pyrin inflammasome formation in the absence of pathogen 
infection. By contrast, either the presence of several bacterial 
toxins or the mutation of pyrin in FMF patients results in lack 
or diminished pyrin phosphorylation, reduced regulation of 
inflammasome assembly and hyperproduction of cleaved 
IL-1β (34). Moreover, a molecular link between pyrin (but 
not NLRP3, AIM2, and NLRC4) inflammasome regulation 
and the mevalonate kinase pathway has also been recently 
reported. Mevalonate kinase deficiency generates systemic 
inflammation with recurrent fever and lymphadenopathy, 
namely, the hyper IgD syndrome (HIDS) and the more severe 
mevalonate aciduria. Mevalonate kinase contributes to the 
inhibition of pyrin expression in an NF-κB-dependent man-
ner through the production of geranyl pyrophosphate, which 
is necessary for repression of pyrin. As a consequence of 
absent mevalonate kinase pathways in HIDS patients, MEFV 
is overexpressed, and pyrin is abnormally activated leading to 
exacerbated inflammatory cytokine release and autoinflam-
mation (35).
ePiGeneTiCS OF AUTOinFlAMMATORY 
DiSORDeRS
Epigenetic is broadly defined as the mitotically heritable changes 
that affect gene expression without affecting genome DNA 
sequence. More specifically, epigenetics encompass mechanisms 
that register, mark or perpetuate gene activity states. It is accepted 
that, due to their upstream connections with transcription factors 
and signaling pathways, epigenetic factors sense and mediate 
interactions between environment (extracellular signals) and the 
genome. The main epigenetic mechanisms comprise DNA meth-
ylation, histone modifications, non-coding RNAs, and chromatin 
remodeling. DNA methylation occurs by the addition of a methyl 
group to the 5′ position of a cytosine followed by guanine (CpG 
dinucleotide). Subsequent demethylation results from the oxida-
tion of 5-methylcytosine catalyzed by ten–eleven translocation 
enzymes, which forms intermediates (5-hydroxymethylcytosine; 
5-formylcytosine; and 5-carboxylcytosine) to yield the final 
unmethylated cytosines; however, recently, it has been described 
that these oxidized intermediates may have independent func-
tional roles on their own merit. Posttranslational modifications 
of different histone amino acid residues are a vast group of epi-
genetic modifications. The functional role of all these epigenetic 
modifications depend on various factors including genomic 
location, and it can be very different in promoters, enhancers, 
and other genomic sites. Myeloid cells are very plastic, and they 
display vast changes in epigenetic modifications in response to a 
variety of environmental stimuli and under pathological inflam-
matory conditions (36).
In monogenic disorders, such as FMF, studies comparing 
patients with the same ancestry living in Turkey or in Germany 
have allowed the determination of the impact of the environment 
on the severity of FMF, in which environmental factors may 
contribute to as much as 12% of the phenotypic variation (37). 
In addition, it has been reported that gains of DNA methylation of 
the FMF causative gene MEFV lead to reduced MEFV expression 
in FMF peripheral leukocytes from 51 FMF patients compared to 
21 healthy controls (38).
In the case of other classical monogenic disorders, evidence 
of epigenetic dysregulation is also starting to emerge from recent 
studies. Analysis of skin biopsies from NOMID patients, compar-
ing skin lesions with both non-lesional skin and normal skin, is 
suggestive of epigenetic regulation, as genes that encode histones 
and enzymes that modify histones were differentially regulated 
in lesional skin. Moreover, two microRNAs, miR-29c and miR 
103-2, were significantly downregulated in lesions, whereas 
some other skin specific miRNAs including miRNAs miR 9-1, 
miR 199a-2, miR 203, and miR 320a, were upregulated (39). 
Nevertheless, a more cell-specific and systematic analysis of the 
contribution of epigenetics in NOMID pathology is required. 
Our group has recently described that activation of monocytes 
and macrophages by inflammatory stimuli, such as cytokines 
GM-CSF and IL-1β, drives TET2-mediated demethylation of 
several inflammasome-related molecules including PYCARD, 
AIM2, IL-1α, and IL-1β. These data led us to further investigate 
the methylation status of inflammasome genes in a cohort of 
CAPS and FMF patients. We found that demethylation of such 
genes is exacerbated in untreated CAPS patients and that this 
demethylation was reverted by anti-IL-1β treatment (40). We pro-
vided evidence for the first time that an epigenetic mechanism, in 
this case DNA methylation, may contribute the decrease in IL-1β 
production threshold in CAPS patients, and provide the basis for 
the discovery of novel biomarkers that could complement the 
diagnosis of autoinflammatory disorders (Figure  3). Evidence 
for epigenetic dysregulation has also been provided in the case 
of complex autoinflammatory disorders such as Behçet’s disease. 
Genome-wide DNA methylation studies in monocytes and 
CD4+ cells of BD patients, during flares and remission, compar-
ing to healthy counterparts have revealed significant differences 
in methylation levels throughout the genome. Moreover, BD 
monocytes displayed 383 differentially methylated CpGs in 228 
genes, whereas CD4+ showed 125 differential CpGs in 62 genes. 
Both hypermethylation and hypomethylation were represented 
in equivalent levels, and GO analysis of affected genes revealed 
FiGURe 3 | epigenetics of autoinflammatory diseases. Epigenetic changes have been described in several autoinflammatory diseases. For example, in the 
case of chronic recurrent multifocal osteomyelitis (CRMO), a failure of histone H3 phosphorylation at serine residue 10 (H3S10p) in the promoter region impairs IL-19 
and IL-10 expression. Also, neonatal-onset multisystem inflammatory disease (NOMID) patients are associated with an increase of miR 9-1, miR 199a-2, miR 203, 
and miR 320a and a decrease of miR 29c and miR 103-2 in their skin. Finally, changes on DNA demethylation dynamics have been recently described in 
cryopyrin-associated periodic syndromes (CAPS) and Familial Mediterranean Fever (FMF).
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an overrepresentation of cytoskeletal remodeling genes in mono-
cytes and antigen processing and antigen presentation in CD4+ 
lymphocytes. Interestingly, BD patients in remission showed 
similar DNA methylation patterns as healthy controls, suggesting 
that changes in global DNA methylation patterns directly reflect 
disease pathology (41). In the case of CRMO, an autoinflamma-
tory disease affecting the bone, an imbalance of proinflammatory 
and regulatory signals has been described. In particular, decreased 
expression of IL10 has been shown to be directly attributed to 
epigenetic dysregulation. CRMO monocytes fail to produce 
IL-10, and related anti-inflammatory cytokine IL-19, upon LPS 
stimulation, which in turn leads to IL-1β overproduction and 
inflammation within the bone. IL10 repression is suggested to 
occur through impaired chromatin remodeling caused by altered 
histone H3 phosphorylation at serine residue 10 at the IL10 proxi-
mal promoter, which also encompasses the regulatory elements 
of the IL19 (CNS1) gene and partially the IL20 gene (CNS2). 
In addition, differential DNA methylation of the IL10 intronic 
enhancer element (I-SRE) and the IL19 CNS1 was also observed. 
This strongly suggests that epigenetic regulation contribute to 
the overall proinflammatory imbalance and pathophysiology in 
CRMO (42, 43). Another set of multifactorial, complex disorders 
are the group of IBDs, typically CD and ulcerative colitis (UC), 
in which genetic predisposition, environmental microbiota, 
and immune responses are the main contributing factors to its 
pathology. Regarding to genetic contribution, twin studies show 
a 50% concordance for monozygotic and 10% for dizygotic twins 
for disease development (16). Using methylation bead arrays to 
compare whole blood from 21 CD adults versus 19 sex-matched 
controls, as well as 16 CD pediatric patients, a specific methyla-
tion profile for CD was determined, which includes differential 
methylation in several immune related genes such as MAPK13, 
FASLG, PRF1, S100A13, RIPK3, and IL21R in patients compared 
to healthy controls (44). Interestingly, the DNA methyltransferase 
gene DNMT3A has been identified by GWAS as a CD susceptibil-
ity gene, which suggests that aberrant DNA methylation may be 
participating in CD etiology (45). Although specific profiles of 
miRNA expression in UC and CD have been described in both 
target tissues and blood, cell type-specific miRNA expression 
data to unambiguously assess causality are still lacking (46).
Altogether, epigenetic dysregulation is emerging as a relevant 
contributing factor of autoinflammatory development, and 
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further investigation would provide valuable insight into their 
pathogenesis that could hint for molecular-tailored treatment.
COnClUSiOn
The possibility of additional causative mechanisms leading to 
exacerbated autoinflammation in both mutated and non-mutated 
pathogenic genes increases the complexity of how autoinflamma-
tory diseases manifest and evolve. It is conceivable that different 
gene variants could behave in a differential manner depending on 
its association with non-genetic background, which in turn is able 
to shape disease presence and severity, ranging from being a true 
causative mutation, a functional polymorphisms or remaining 
silent (47). In this respect, in addition to more in-depth genetic 
studies using massively parallel sequencing techniques (such 
as whole-exome sequencing and targeted deep resequencing), 
epigenetic genome-wide profiling studies could be of great value 
as they would inform of non-genetic landscapes that contribute 
to pathogenicity. Moreover, current genetic diagnosis of a few 
candidate genes would expand potential biomarkers taking 
into account clinical and molecular traits other than described 
mutations. Overall, the identification of epigenetic dysregulation 
contributing to autoinflammation will allow us to address envi-
ronmental contribution to autoinflammatory syndromes.
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